Streetbeat News

Stock Prices

VRTX

Vertex Pharmaceuticals Incorporated (VRTX) shares are trading higher following the announcement of better-than-expected fourth quarter results. Additionally, the company has issued strong guidance for the first quarter and full year of 2024, indicating positive future performance.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:47 pm

QCOM

Recent analysis of options trading activity for Qualcomm (NASDAQ:QCOM) shows a bullish sentiment among investors, with 56% of trades being bullish and 43% bearish. Notable trades include both puts and calls, targeting a price range of $105.0 to $175.0 for Qualcomm over the last 3 months. The company, a major player in wireless technology and chip design, is currently trading at $156.94, up 0.7%, but may be overbought according to RSI readings. Analysts have issued varied ratings, with a consensus target price of $163.0.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:47 pm

SNAP

Significant options activity has been observed in Snap Inc. (NYSE:SNAP), with a bearish sentiment prevailing among big-money investors. Benzinga's options scanner revealed 9 unusual trades, with a split sentiment of 33% bullish and 66% bearish. The trades indicate a targeted price range for SNAP between $9.0 and $15.0 over the next 3 months. The largest trades include both bullish and bearish positions, with notable volumes and open interests. Snap's current trading volume is 4,261,049, with a slight price increase of 0.18%, and an RSI indicating a potential oversold condition. Analyst ratings over the past month suggest a mixed outlook, with target prices ranging from $11 to $20.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:47 pm

DAVA

Endava shares are trading lower following the release of their Q2 earnings report.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:46 pm

OKTA

B of A Securities analyst Madeline Brooks upgraded Okta (NASDAQ:OKTA) from Underperform to Buy and increased the price target from $64 to $135.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:45 pm

IRWD

Ironwood Pharmaceuticals' shares dropped following the announcement that its Phase 3 trial of apraglutide failed to meet two key secondary endpoints. The trial was evaluating the efficacy of a once-weekly subcutaneous administration of apraglutide.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:45 pm

ACMR

Goldman Sachs analyst Allen Chang has upgraded ACM Research (NASDAQ:ACMR) from Neutral to Buy and set a new price target of $39.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 3:43 pm

TSLA

Ford Motor Company (NYSE:F) has announced that its electric vehicle (EV) customers, specifically those owning Ford F-150 Lightning and Mustang Mach-E, now have access to Tesla Inc's (NASDAQ:TSLA) Supercharger network. This access includes over 15,000 Tesla Superchargers, effectively doubling the charging options for Ford's EV customers. The partnership, which was first announced in May 2023, allows Ford EV owners to use a fast-charging adapter for free until June 30, 2024, after which it will cost $230. This collaboration is seen as a significant step towards improving EV infrastructure and reducing barriers to EV adoption.

Portfolio Pulse from Chris Katje

February 29, 2024 | 3:43 pm

BAND

CRM

DUOL

NVDA

OKTA

PDCO

PSTG

SAH

WES

Top Wall Street analysts have updated their price targets and ratings for several US-listed companies, including NVIDIA, Okta, Bandwidth, Pure Storage, Macy's, Salesforce, Western Midstream Partners, Duolingo, Patterson Companies, and Sonic Automotive. The changes include both upgrades and downgrades, with significant price target adjustments reflecting analysts' revised expectations for these companies.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 3:40 pm

CPRX

RNA

SILK

As of Feb. 29, 2024, Avidity Biosciences (RNA), Catalyst Pharmaceuticals (CPRX), and Silk Road Medical (SILK) are considered overbought in the health care sector, with RSI values above 70, indicating potential short-term performance concerns. Avidity Biosciences reported a wider-than-expected quarterly loss but expects a transformative year with its Phase 3 HARBOR trial. Catalyst Pharmaceuticals exceeded quarterly expectations with robust revenue growth. Silk Road Medical posted a narrower-than-expected loss, focusing on deepening TCAR adoption.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 3:40 pm